Vagni Paola, Perlini Laura E, Chenais Naïg A L, Marchetti Tommaso, Parrini Martina, Contestabile Andrea, Cancedda Laura, Ghezzi Diego
Medtronic Chair in Neuroengineering, Center for Neuroprosthetics and Institute of Bioengineering, School of Engineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Laboratory of Local Micro-environment and Brain Development, Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Genoa, Italy.
Front Neurosci. 2019 Sep 10;13:945. doi: 10.3389/fnins.2019.00945. eCollection 2019.
Inherited retinal dystrophies (IRDs) are a large and heterogeneous group of degenerative diseases caused by mutations in various genes. Given the favorable anatomical and immunological characteristics of the eye, gene therapy holds great potential for their treatment. Our goal is to validate the preservation of visual functions by viral-free homology directed repair (HDR) in an autosomal recessive loss of function mutation. We used a tailored gene editing system based on clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) to prevent retinal photoreceptor death in the retinal degeneration 10 (Rd10) mouse model of retinitis pigmentosa. We tested the gene editing tool and then used subretinal electroporation to deliver it to one of the retinas of mouse pups at different stages of photoreceptor differentiation. Three months after gene editing, the treated eye exhibited a higher visual acuity compared to the untreated eye. Moreover, we observed preservation of light-evoked responses both in explanted retinas and in the visual cortex of treated animals. Our study validates a CRISPR/Cas9-based therapy as a valuable new approach for the treatment of retinitis pigmentosa caused by autosomal recessive loss-of-function point mutations.
遗传性视网膜营养不良(IRDs)是一大类由各种基因突变引起的退行性疾病,具有高度异质性。鉴于眼睛有利的解剖学和免疫学特征,基因治疗对其治疗具有巨大潜力。我们的目标是通过无病毒同源定向修复(HDR)来验证常染色体隐性功能丧失突变中视觉功能的保留情况。我们使用了一种基于成簇规律间隔短回文重复序列(CRISPR)/CRISPR相关蛋白9(Cas9)的定制基因编辑系统,以防止视网膜色素变性的视网膜变性10(Rd10)小鼠模型中的视网膜光感受器死亡。我们测试了该基因编辑工具,然后使用视网膜下电穿孔将其递送至处于光感受器分化不同阶段的小鼠幼崽的一只视网膜。基因编辑三个月后,与未治疗的眼睛相比,治疗的眼睛表现出更高的视力。此外,我们在移植的视网膜和治疗动物的视觉皮层中均观察到光诱发反应的保留。我们的研究验证了基于CRISPR/Cas9的疗法是治疗由常染色体隐性功能丧失点突变引起的视网膜色素变性的一种有价值的新方法。